USPTO 2015–2025 USPTO PatentsView US Corporation

Voyager Therapeutics, Inc.

USPTO PatentsView assignee record - 41 granted patents across 13 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Explore the portfolio See the ranking

Total patents granted

CPC technology areas

23.6

Avg claims per patent

+3200%

5-year grant velocity

The verdict

According to USPTO PatentsView, Voyager ranks #7,961 of 50,000 tracked US assignees by granted-patent volume, with 41 patents across 13 technology areas.

#7,961
of 50,000 US assignees by volume: Top 8%
by Innovation Score (53.8/100): 23.6
avg claims per patent: +3200%
grant velocity, last 5 yrs

Portfolio overview

Voyager Therapeutics, Inc. has been granted 41 US utility patents between 2019 and 2025, placing Voyager Therapeutics, Inc. at #7,961 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 23.6 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a US Corporation, Voyager Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Voyager sits between Universiteit Leiden (41 patents, rank #7,954) and Westfälische Wilhelms-universität Münster (41 patents, rank #7,962) - the closest US assignees by grant volume. The composite Innovation Score of 53.8/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 33 grants, compared with 1 in the 2015–2019 window, a +3200% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Voyager Therapeutics, Inc.'s 23.6 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 13 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Universiteit Leid…

41
UniversitÉ Joseph…

41
Unity Biotechnolo…

41
University of Sha…

41
Versa Networks

41
Vitaworks IP

41
Volvo Group Canada

41
WestfÄLische Wilh…

41
Voyager Therapeut… ◀

41

What this shows Voyager holds 41 patents at rank #7,958, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Voyager

By rank, the assignees closest to #7,958 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Voyager's primary technology class.

Voyager's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Voyager Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	2.4%
2020	4	9.8%
2021	6	14.6%
2022	6	14.6%
2023	5	12.2%
2024	12	29.3%
2025partial year	7	17.1%

Which technologies does Voyager Therapeutics, Inc. patent most?

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 39

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 24

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 24

C07K - PEPTIDES 17

C12Y - ENZYMES 16

A01K - ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS 4

C40B - COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES 3

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 2

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 2

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 2

A61M - DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR 1

G01R - MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES 1

G16H - HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA 1

Top 13 of 13 technology areas

Grant record at a glance

Portfolio Volume 41 grants

CPC subclasses 13

Avg. claims / grant 23.6

Velocity +3200%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#7,961

of 50,000 tracked assignees

Innovation Score

53.8 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Voyager Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Voyager Therapeutics, Inc. ranks #7,961 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Voyager Therapeutics, Inc. hold?

Voyager Therapeutics, Inc. holds 41 US utility patents granted between 2019 and 2025, spanning 13 technology areas.

What is Voyager Therapeutics, Inc.'s Innovation Score?

Voyager Therapeutics, Inc. has an Innovation Score of 53.8 out of 100 (top 8% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Voyager Therapeutics, Inc. focus on?

Voyager Therapeutics, Inc.'s top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 39 patents. Grants appear in 13 CPC subclasses total.

Is Voyager Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Voyager Therapeutics, Inc.'s recent grant velocity is +3200% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Voyager Therapeutics, Inc.'s patents?

Voyager Therapeutics, Inc.'s patents average 23.6 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Voyager Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Voyager's 41 grants land it in the top 8% by Innovation Score, but volume alone doesn't tell you where the strength sits.

Read that count against the largest US assignees before treating it as dominance - Voyager ranks #7,961 of 50,000. Top 50 holders
Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.